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These antigens can easily be encoded in
next-generation nucleic acid-based vac-
cines as novel tools to tackle increasing
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immunopeptidomics andmRNA vaccineAntimicrobial resistance is an increasing global threat and alternative treatments
substituting failing antibiotics are urgently needed. Vaccines are recognized as
highly effective tools to mitigate antimicrobial resistance; however, the selection
of bacterial antigens as vaccine candidates remains challenging. In recent years,
advances in mass spectrometry-based proteomics have led to the development
of so-called immunopeptidomics approaches that allow the untargeted discovery
of bacterial epitopes that are presented on the surface of infected cells. Especially
for intracellular bacterial pathogens, immunopeptidomics holds great promise to
uncover antigens that can be encoded in viral vector- or nucleic acid-based
vaccines. This review provides an overview of immunopeptidomics studies on
intracellular bacterial pathogens and considers future directions and challenges
in advancing towards next-generation vaccines.technology prelude an increase in
screens on intracellular bacterial infection
models.
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(F. Impens).A need for next-generation antibacterial vaccines
With the advent of antibiotics in the first half of the 20th century, many bacterial diseases lost their
devastating dominance over humankind. Commonplace outbreaks of the plague, cholera, and
many other bacterial diseases claimed a death toll in the hundreds of millions. A combination of
improved sanitary standards, elevated living conditions, and the availability of antibiotics massively
reduced these outbreaks; however, (over)use of antibiotics has accelerated the emergence of an-
timicrobial resistance (AMR). Annual AMR-related deaths are predicted to skyrocket from 700 000
in 2019 to 10 million globally in 2050 [1]. Hence, the World Health Organization (WHO) and the US
Centers for DiseaseControl and Prevention (CDC) have identified pathogenic bacteria for which the
AMR situation is particularly dire, including several intracellular pathogens such as Salmonella,
Shigella spp. and Mycobacterium tuberculosis (Mtb) [2,3]. In addition to stringent antibiotic stew-
ardship and fast development of novel antibacterial drugs by initiatives like the AMR Action Fund
[4], vaccines are regarded as highly effective tools to mitigate resistance (recently reviewed in [5]).
The prophylactic use of bacterial vaccines prevents infections, thereby reducing the need for anti-
biotic prescription andminimizing selective drug pressure [5]. In contrast to antibiotics, antibacterial
vaccines remain effective against their target pathogen over time. Furthermore, high vaccination
rates create a herd immunity that protects susceptible individuals who cannot be effectively vacci-
nated, like the elderly, immunosuppressed, or chronically sick people [5].
Several antibacterial vaccines have been utilized successfully in the past and are routinely used
nowadays, typically providing a high degree of immunity and safety. These include vaccines against
tetanus, diphtheria, and pertussis, against Haemophilus influenzae type B (Hib), pneumococcus,
as well as meningococcus [6,7]. There are also vaccines against typhoid fever, anthrax, and chol-
era that are administered in, and for those traveling to, endemic areas. In contrast, for tuberculosis
(TB) as a major global health burden, the only readily available and inexpensive vaccine, Bacillus
Calmette–Guérin (BCG), does not offer efficient and reliable protection against all forms of the dis-
ease [8–10]. Efforts to bolster the protection afforded by BCG – by using it in combination with
MVA85A (modified vaccinia Ankara 85A) – have not yielded significant improvements [11]. MostTrends in Microbiology, Month 2021, Vol. xx, No. xx https://doi.org/10.1016/j.tim.2021.04.010 1
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only the tuberculosis and typhoid fever vaccines target intracellular pathogens. Being protected
from the humoral, and parts of the cellular immune response, as well as several antibiotics inside
host cells, intracellular bacteria often present a particular clinical challenge rendering vaccine devel-
opment even more crucial [12]. Many intracellular pathogens are also capable of persisting in host
cells by entering a dormant state such as Mtb, Salmonella, Bartonella, uropathogenic Escherichia
coli or Brucella [13].
Many recent antibacterial vaccines, like the ones against Hib, meningococcus, and streptococcus,
are conjugate vaccines with bacterial polysaccharides bound to carrier proteins. Conjugate vac-
cines achieve high protective efficacy, even in young children, but suffer from relatively long devel-
opment times and are mainly targeted against extracellular bacteria [5,7,14]. For intracellular
pathogens, the development of effective vaccines has long been held back by a lack of antigen
knowledge along with the inability of most vaccine platforms to elicit strong cytotoxic responses.
The latter can now be overcome by next-generation vaccines, including viral vector, DNA, and
mRNA vaccines that induce both humoral and cytotoxic immune responses and allow relatively
fast development times (Box 1, and reviewed in detail in [15–17]). All three approaches introduce
the genetic information encoding the actual antigen into host cells for intracellular antigen synthesis,
resulting in elevated cytotoxic immune responses.
The question remains, though, of which bacterial antigen(s) to encode into these vaccine plat-
forms. In contrast to viruses, the potential antigen palette for pathogenic bacteria is significantly
more diverse, with typically several thousand genes per bacterium rendering the choice of the
correct antigen a challenging task. This is illustrated by the limited coverage of most intracellular
bacterial pathogens in the Immune Epitope Database (IEDB, www.iedb.org) as depicted in
Figure 1 [28].
Immunopeptidomics, a powerful approach for antigen discovery
Vaccine development has come a long way since Pasteur postulated his classical vaccinology
approach of isolating, inactivating, and injecting disease-causing agents to protect patients.
Reverse vaccinology, as spearheaded by Rino Rappuoli in 2000, utilizes full pathogen genomesBox 1. Next-generation nucleic acid-based vaccines
Viral vectors (such as adenoviral vectors) encode the antigen(s) to be delivered, which are typically surface-exposed anti-
gens such as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein, within a nonpathogenic
viral vehicle. While viral vectors are a flexible platform, allowing the rapid adaption to new antigen targets of emerging path-
ogens, they might suffer from pre-existing immunity against the vector, neutralizing the vaccine before cellular uptake. This
is a particular problem for booster vaccinations using the same viral vector and also the relatively costly cell-based produc-
tion of viral vectors present a challenge [17]. In the case of DNA vaccines, the antigen-encoding DNA is introduced directly
or lipid-encapsulated into host cells. Advantages of DNA vaccines include high stability and absence of pre-existing immu-
nity, while reduced expression efficiency has been an issue due to the need of nuclear import before transcription into an-
tigen-encoding mRNA and nuclear export prior to antigen translation [16]. In contrast, mRNA-based vaccines introduce
the antigenic information via mRNA to omit nuclear import, allowing direct antigen translation, and like DNA vaccines, they
are not subject to pre-existing immune defenses. While it has been known since the nineties that exogenous transcribed
mRNA can be used to express proteins in vivo [18], only in recent years has mRNA emerged as a promising vaccination
platform technology. In vitro transcribed (IVT) mRNA showed its utility as a vaccine format to promote prophylactic protec-
tion against infections with viruses such as Zika [19] and influenza [20]. A number of modifications to the vector used to
produce the mRNA, as well as to the synthetic mRNA itself, have further ameliorated the biologic properties of the IVT
mRNA [21]. In the past year, the SARS-CoV-2 pandemic greatly accelerated the clinical entry of next-generation vaccines,
especially mRNA vaccines conferring over 90% protection against coronavirus disease 2019 (Covid-19) [22,23] This has
proven that mRNA-based vaccines have evolved to safe, well-tolerated and very effective vaccines against viral infections.
However, their potential in the context of intracellular bacterial infections remains largely unexplored [24–26]. mRNA vac-
cines therefore represent a promising alternative to conventional vaccines based on their high potency, capacity for short
development time, as well as their potential for low-cost manufacture and safe administration [27].










































































































Figure 1. Antigenic coverage for
intracellular bacterial pathogens.
The number of protein antigens for
a selection of intracellular bacterial
pathogens is displayed as a fraction of
each pathogen's total proteome. Black
parts of the bars indicate MHC class I-
presented antigens, while in gray all
non-MHC class I-presented antigens
are depicted. Numbers above the bars
indicate the total antigen count per
pathogen retrieved from the Immune
Epitope Database (IEDB) on February
22, 2021 [28]. While, for Mtb, more
than 20% of its protein-coding genes
have been identified as antigen, for
most other bacteria less than 5% of
their proteins were reported as
antigen. Moreover, only a subset of
these antigens gives rise to MHC class I-restricted epitopes and might elicit cytotoxic immune responses. While the
number of immunodominant antigens is likely much smaller than the total protein repertoire, it can be assumed that the list
of bacterial antigens discovered so far is far from complete and that many antigens still await their discovery as vaccine
candidate.
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surface proteins as suitable vaccine candidates [29]. Recombinantly expressed in E. coli or
other systems, the candidate antigens’ immunogenicity is evaluated in animal models prior to
clinical studies. This way, a serogroup B meningococcal vaccine, as well as vaccine candidates
against group B streptococcal infection, Chlamydia, antibiotic-resistant Staphylococcus aureus,
and Streptococcus pneumoniae were successfully developed [30]. Building on the initial reverse
vaccinology platform, reverse vaccinology 2.0 was gradually implemented in the past decade
harnessing contemporary platforms like B cell repertoire deep sequencing, structure-based
antigen design, and mass spectrometry-based proteomics [31].
Immunoproteomics, as a collection of techniques that readily allow the detection of antigenic
peptides or proteins, has benefitted greatly from recent quantum leaps in mass spectrometry
(MS) and data analysis [32]. Methods for investigating extracellular antigens include variants of
immunocapture MS for circulating immune complexes (CICs), electroimmunoprecipitation of an-
tibody–antigen complexes, and multiple affinity protein profiling (MAPPing) [32]. Also, serological
proteome analysis (SERPA) as well as array-based approaches have been utilized for antigen
analysis [32]. All of these methods, however, require antibody secretion and can therefore
only detect targets of the humoral immune response. Antibody-independent detection of
antigens can be realized with another type of immunoproteomic methodology known as
immunopeptidomics.
Immunopeptidomics aims to detect antigens as peptides that are presented on cell surfaces via
major histocompatibility complexes (MHCs), commonly termed immunopeptides, MHC-
associated peptides, or MHC ligands. These immunopeptides are antigen fragments of 8–25
amino acids that are loaded intracellularly onto MHC complexes before transportation to the
cell surface for T cell inspection. The two classes of MHC molecules, MHC class I and II, facilitate
presentation of antigens from cytosolic and vacuolar/extracellular antigens, respectively, and they
bind different T cell populations with distinct functionalities. While MHC II expression is restricted
mainly to professional antigen-presenting cells (APCs), MHC I is present on all nucleated cells and
binds CD8 cytotoxic T cells to initiate cell death in compromised cells. The resulting cytotoxicTrends in Microbiology, Month 2021, Vol. xx, No. xx 3
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spotlighted in this review (Box 2).
Following isolation and purification, MHC-presented peptides can be identified by MS. Techno-
logical quantum leaps over the past 30 years have allowed the field to mature, and identification
of thousands of epitopes per study is now commonly achieved. In 1992 the laboratory of Donald
Hunt successfully identified the first HLA peptide ligands from HLA allele A*0201 by liquid
chromatography–tandem mass spectrometry (LC-MS/MS) [51]. Since this first study, HLA-bound
peptide elution and detection by LC-MS/MS has remained the method of choice for measuring
antigenic peptides. Isolation of immunopeptides can be achieved by two methods. Firstly, mild acid
elution (MAE) directly from the surface of intact cells allows fast and simple immunopeptide harvest
but suffers from contaminant peptide coelution and inseparability of MHC class I and II peptides
[52]. Secondly, immunoprecipitation (IP) of intact MHC–peptide complexes after cell lysis requires
large amounts of specific antibodies and elevated sample preparation times, while delivering
improved immunopeptide enrichment and increased numbers of immunopeptide identifications
[52]. Furthermore, IP allows separation of MHC class I and II peptides, and is compatible with frozen
samples, while MAE is not. Unsurprisingly, IP is therefore applied for most immunopeptidomics
studies (Figure 2).
The major limitation for immunopeptidomics is the large amount of starting material required,
typically around several hundred million cells, or 1 g of tissue, since the abundance of
immunopeptides is usually extremely low [38,53]. Hence, sample processing steps and surface ex-
posure are to be minimized. A detailed protocol on immunopeptide isolation has been described
elsewhere [53]. After isolation, immunopeptides are analyzed by LC-MS/MS, utilizing more sophis-
ticated workflows than standard proteomics by implementation of special derivatization,Box 2. Cellular immunity based on MHC presentation
The MHC class I pathway features proteasomal digestion of cytosolic intracellular antigens with optional further trimming
by other proteases, such as endoplasmic reticulum aminopeptidase 1 and 2 (ERAP1 and 2), to a peptide length of around
8–12 amino acids, enabling loading onto MHC I complexes in the endoplasmic reticulum (ER). Introduction into the ER
occurs via the transporter associated with antigen processing (TAP) before binding to MHC class I molecules and
transportation of the entire complex to the cell surface via the Golgi apparatus for CD8 T cell surveillance and elimination
of pathogen-infected or malignant cells. In healthy cells, class I peptides result from defective ribosomal products (DRiPs)
or retiree proteins favoring abundant, short-lived proteins [33]. While standard proteasomes facilitate continuous
monitoring of correct protein synthesis, immunoproteasomes occur in immune cells or upon immune stimulation. Primarily
responsible for intracellular microbial protein digestion, immunoproteasomes localize to the ER and utilize altered peptide-
cleavage properties, creating a distinct immunopeptidome enhancing efficient pathogen-derived antigen presentation via
MHC class I [34–40]. Besides proteolysis, the proteasome might also concatenate distant protein fragments by
proteasome-catalyzed peptide splicing (PCPS) forming novel, antigenic peptide sequences [41]. The abundance of
spliced peptides is currently debated to be between 0.1 and 34% of all presented immunopeptides [42–44] and has been
recently reviewed in [45]. Importantly, T cell responses to several intracellular bacteria-derived spliced peptides have been
demonstrated [46,47]. In infection, PCPS could benefit immunity by circumventing minor antigen mutations providing
stable epitopes for persistent immune responses [48].
Human MHC molecules are termed human leukocyte antigens (HLAs) and both MHC I and MHC II are each divided into
classical and nonclassical HLAs. The three classical MHC I genes (HLA-A, HLA-B, HLA-C) are codominantly expressed
with thousands of diverse alleles using variable peptide-binding specificities facilitating presentation of a broad antigen
spectrum. Allele frequencies vary greatly, with a dozen alleles covering the majority of most local, homogeneous popula-
tions, while different ethnic groups and distant geographical regions present with diverging dominant alleles, having
substantial implications for antigen prioritization and vaccine development [49].
In contrast toMHC I, MHC class II binding peptides are longer, with around 15–24 amino acids, and result from exogenous
antigens endocytosed by APCs followed by subsequent endolysosomal degradation [50]. Similar to MHC I, there are three
classical, highly polymorphic MHC II genes (HLA-DP, HLA-DQ, HLA-DR) creating a plethora of possible combinations of
alleles.
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Figure 2. IP-based immunopeptidomics workflow. Cells or tissues are lysed by mild detergents in combination with sheer stress [53] and lysates are cleared and
sterile-filtered to remove residual debris and/or pathogens. Cleared lysates containing intact MHC–peptide complexes are incubated with immunoaffinity columns. For
human samples, the high-quality pan-class I antibody from the W6/32 hybridoma cell line is commonly used, while for all classical MHC II alleles (HLA DR, DQ, and DP)
the IVA12 hybridoma-derived antibody is available. The amount of antibody required for 1E9 cells is in the mg range, posing a significant cost factor. The MHC-specific
antibody is typically covalently cross-linked to protein A- or G-coated beads to avoid antibody coelution and sample contamination. Following several washes, MHC–
peptide complexes are eluted from the immunoaffinity columns by acidic elution. Eluates are further purified to remove MHC molecules by liquid chromatography,
ultrafiltration, or C18-based solid-phase extraction to separate short-chain hydrophilic immunopeptides from longer hydrophobic MHC molecules. For liquid
chromatography–tandem mass spectrometry (LC-MS/MS) analysis of purified immunopeptides, highly sensitive, high-resolution instruments and customized
parameters are imperative for a successful analysis. Data analysis of the raw data can be carried out by classical proteomics software packages such as MaxQuant or
more sophisticated solutions like PEAKS studio [53]. Abbreviation: TFA, trifluoroacetic acid.
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translational modifications (PTMs) (Box 3).
Untargeted identification of novel bacterial antigens
Immunopeptidomics is extensively applied for tumor-associated antigen discovery, but its use in
infection models is rather limited [69–74]. Next to several studies on viral and parasitic pathogens,
bacterial infection models are historically understudied by immunopeptidomics. Recently
however, more studies on bacterial infection models are being conducted in light of AMR
emergence.
Mycobacterium tuberculosis
The first immunopeptidomics study on bacterially infected cells was reported in 2002 by the Hunt
laboratory, identifying antigenic peptides from Mtb strain H37Ra [75]. From one billion infected
human U937 monocyte cells expressing MHC class I HLA-A*02:01, three nested peptides
from the Mtb isoniazid inducible gene protein iniB (Rv0341) were identified (Rv034133-42,
Rv034133-44, and Rv034133-45) next to one peptide from heat-shock protein hsp65 and one pep-
tide from galactofuranosyl transferase glfT2. The identity of the three nested peptides was
confirmed by LC-MS. MHC I binding affinity, as well as immunogenicity, was confirmed by
CD8 T cell-induced lysis of peptide-presenting and Mtb-infected cells.
A decade later, Cayabyab and colleagues infected C57BL/6 mice with Mtb strain H37Rv identi-
fying MHC I peptides from splenic adherent cells [76]. From ~500 identified immunopeptides,
the authors sequenced 4 peptides originating from Mtb, of which one peptide was specific for
Mtb and not present in other bacteria. The authors encoded the parent protein of this peptide,Trends in Microbiology, Month 2021, Vol. xx, No. xx 5
Box 3. Advanced LC-MS/MS and data analysis pipelines for immunopeptides
For immunopeptidomics, the LC-MS/MS setup needs to be well maintained and suited for identification of ultra-low abun-
dant analytes. Nano-flow liquid chromatography (nanoLC), as one of the most sensitive separation technologies, is typi-
cally coupled to a high-resolution mass spectrometer enabling immunopeptide separation for complexity reduction
before the peptide measurement. Therefore, high-performance separation columns, using sub-2μm chromatographic
beads or micropillar arrays, are ideal for peptide separation [54]. Immunopeptides are usually analyzed by LC-MS/MS in
their native state, termed label-free; however, chemical derivatization and isotopic labeling were recently found to improve
detectability of these short, nontryptic peptides by promoting positive charges on peptides, which are essential for
successful peptide ionization during LC-MS/MS analysis [55–57]. Utilizing these techniques, efforts are ongoing to further
reduce the required sample input by peptide amplification strategies [58]. MS fragmentation methods to infer
immunopeptide sequence information include collision-induced dissociation (CID) or higher-energy collisional dissociation
(HCD), but also sophisticated techniques like EThcD combining electron transfer dissociation (ETD) with HCD to generate
more diverse fragment ions and to improve identification rates and detection of post-translationallymodified peptides [59,60].
Peptides carrying PTMs, such as phosphorylation, O-linked glycosylation, acetylation, formylation, N-myristoylation,
citrullination, arginine (di)methylation, cysteinylation, and deamidation, are known to be presented via MHC class I, potentially
altering peptide–MHC interactions and CD8 T cell responses [61–64]. Identification of modified immunopeptides poses a
particular challenge due to their low abundance and instability. Hence, specific enrichmentmethodologies and enzyme inhib-
itors are used during lysis to prevent PTM degradation [65]. We are now only starting to understand the impact of PTMs on
antigen presentation, an important subject for future immunopeptidomics studies, especially in the context of infection, since
PTMs are known to play key roles in host–pathogen interactions [66]. Data analysis of MS raw data is the crucial final step of
immunopeptide identification, and algorithms to do so have improved substantially in recent years. Due to the extremely var-
iable cleavage options for proteasome-generated immunopeptides, the number of theoretical peptides for presentation is ex-
tremely high, hampering sensitive and accurate matching between mass spectra and peptide sequences using standard
proteomics software. Current sophisticated approaches to circumvent this problem utilize MHC sequence motif-guided ap-
proaches, innovative false discovery rate estimation techniques, or de novo peptide sequencing. The latter approach avoids
matching of raw spectral data against a predefined protein sequence database but matchesmass differences between pep-
tide fragments directly to amino acid masses [67,68].
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prime/boost immunization experiment in mice, resulting in a strong CD8 T cell response.
In 2017, McMurtrey and colleagues reported on the immunopeptidome presented upon infection
with Mtb strain H37Rv on nonclassical and low-polymorphic MHC class I HLA-E molecules [77].
Next to over 1200 host immunopeptides, 28 Mtb peptides from 13 different proteins were iden-
tified from HLA-E molecules secreted from infected human glioblastoma U373 cells [78,79]. All
Mtb epitopes were confirmed by synthetic peptide LC-MS/MS, and 12 of them were recognized
by T cells from healthy donors, latent or active TB patients. The most commonly recognized epi-
tope, Rv0634A19-29, showed restriction to HLA-E. Interestingly, eight of the Mtb antigens were
either secreted or membrane-bound, which is consistent with the current belief of easier acces-
sibility of peripheral bacterial antigens. Half of the Mtb peptides originated from the Esx protein
family, crucial for the ESX-1 secretion system missing in BCG. Hence, it is suggested that loss
of this secretion system and associated antigens reduces the HLA-E-displayed epitope reper-
toire, thereby limiting HLA-E-restricted T cell expansion in BCG vaccination.
Recently, a study by Bettencourt et al. on BCG-infected human THP1 macrophages reported 43
MHC I and 94 MHC II epitopes from 112 BCG proteins next to 23 894 MHC I and 17 599 MHC II
host peptides [80]. In addition to standard infection conditions, the authors used interferon-
gamma (IFNγ) and interleukin-10 (IL10) antibodies to increase MHC II expression, as well as
heat-killed BCG, avoiding pathogen-mediated downregulation of antigen presentation. Stringent
filtering along with spectral validation and T cell response measurements in peripheral blood
mononuclear cells (PBMCs) from BCG-vaccinated donors, latent or active TB patients, resulted
in a comprehensive dataset, including four BCGpeptides with acetylated, methylated, or oxidized
residues. Previous unrelated studies additionally identified palmitoylated, formylated, and biotinyl-
ated Mtb epitopes [81–83]. Again, most BCG antigens presented were associated with the cell6 Trends in Microbiology, Month 2021, Vol. xx, No. xx
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iments were prioritized, and further filtering for high expression levels yielded three antigens – glfT2,
fas, and Ag85A – that were included in an Mtb vaccination challenge study. glfT2 and Ag85A had
been identified in previous studies [75,84], and the authors also tested iniB and PPE15 as previ-
ously detected antigens [75,77,84]. BCG vaccination was followed by two boosts with viral
vectors encoding the selected antigens before aerosol infection with Mtb Erdman. Encoding
glfT2, fas, and iniB as single antigens resulted in a subtle, but significantly lower bacterial load in
the lungs. Combined delivery of all five antigens, however, resulted in a nearly tenfold reduction
in bacterial load in both lungs and spleens, indicating that especially combinations of antigens iden-
tified by immunopeptidomics hold great potential for novel vaccine formulations.
Chlamydia muridarum and Chlamydia trachomatis
In 2008 the laboratory of Robert Brunham reported onmurine bone-marrow-derived dendritic cells
(BMDCs) infected with Chlamydia muridarum, detecting one MHC I and 13 MHC II Chlamydia
peptides from nine proteins besides 509 murine self-peptides [85]. Chlamydia-specific CD4
T cells recognized the identified MHC II epitopes, and dendritic cells (DCs), pulsed with a pool of
eight MHC II peptides, provided partial protection against genital and intranasal Chlamydia infec-
tion. Sequence conservation assessment of the C. muridarum peptides in Chlamydia trachomatis
revealed high sequence homology between the MHC II immunopeptides of all but two proteins, in-
dicating that most epitopes might also hold antigenic relevance for C. trachomatis infection in
human hosts. In a follow-up study, the authors used eight of the previously detected antigens
and identified PmpG-1, PmpE/F-2, and RplF as immunodominant Chlamydia antigens providing
significant protection against C. muridarum infection in mice [86]. Interestingly, PmpG-1, PmpE/
F-2 are bacterial membrane proteins. A further study by this laboratory compared the MHC
class II immunopeptidome of BMDCs pulsed with live and dead C. muridarum elementary bodies
(EBs, a metabolically inactive spore-like form of Chlamydia), revealing that infection with live EBs
resulted in elevated MHC class II presentation of bacterial peptides [87]. For live EBs, 45
immunopeptides from 13 proteins were identified including PmpG and PmpE/F-2, while only six
peptides from three proteins were found for inactivated EBs. Immunization with live EBs also pro-
vided improved protection in a mouse model. In another study, the same group identified MHC II
peptides from infected BMDCs isolated fromC3Hmice, instead of C57BL/6mice [88]. From differ-
ent MHC alleles, peptides from PmpG and PmpF were again identified from the C3H BMDCs. The
authors also infected C57BL/6 BMDCs with C. trachomatis, the typical pathogen in humans, and
identified only PmpG as a shared antigen with C. muridarum in both mouse strains. This antigen
also showed immunodominance and high protection levels in mice with prolonged presentation
on splenic APCs evenmonths after clearing primary infection [89,90], representing an ideal vaccine
candidate along with other Pmps [91]. Abundance, cellular location and expression kinetics were
suggested to play predominant roles for pathogen protein presentation and antigenicity as the
study revealed a total of four Pmps, important for adhesion to human epithelial cells, as well as
MOMP, all abundant outer-membrane proteins [92,93]. AsChlamydia replicates almost exclusively
in epithelial cells during in vivo infection, the Brunham laboratory recently investigated the
immunopeptidome of epithelial cells infected with C. muridarum after IFNγ stimulation to boost
MHC class I and initiate MHC class II expression [94]. The authors chose Bm1.11 murine oviduct
epithelial cells due to partially matching MHC alleles with the previously studied C57BL/6
mouse BMDCs. Among 1138 MHC I and 431 MHC II peptides, 26 and four of these peptides
were derived fromChlamydia, respectively. Surprisingly, there was no overlap with the previous
immunopeptidomes from infected DCs, neither at the epitope level nor the antigen level.
Furthermore, CD4 T cells from C. muridarum-recovered mice did not recognize any dominant
MHC II-boundChlamydia peptides presented on epithelial cells, having substantial implications
for vaccine development.Trends in Microbiology, Month 2021, Vol. xx, No. xx 7
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Next to Chlamydia, the Brunham laboratory also applied their immunopeptidomics pipeline to
Salmonella Typhimurium-infected mouse BMDCs, identifying 1891 MHC I and 617 MHC II pep-
tides [95]. Some 87 MHC II peptides from 53 proteins, and 23 MHC I peptides from 23 proteins,
were derived from Salmonella. Antigenicity validation of the top-scoring 12 MHC II peptides re-
vealed that four peptides elicited an IFNγ response by CD4 T cells isolated from persistently in-
fected mice.
Listeria monocytogenes
In 2018 Graham et al. reported an algorithm for the genome-wide prediction of MHC class II-
restricted immunodominant epitopes termed BOTA (bacteria-originated T cell antigen). The au-
thors identified MHC class II-bound peptides from L. monocytogenes-infected, H2-IA-
expressing mouse BMDCs using an isobaric tagging LC-MS/MS approach [96]. Starting from
their 3671 identified mouse immunopeptide sequences, they trained BOTA, followed by verifica-
tion of the algorithm with the 48 Listeria-derived unique sequences. Of the 17 BOTA-predicted
Listeria epitopes, nine were indeed identified by LC-MS/MS. In total, 48 partially nested Listeria
peptide sequences were identified by MS, comprising 26 individual epitopes from 21 antigens.
Nine of these Listeria peptides carried deamidated or oxidated residues, while previously only
acetylated and formylated Listeria epitopes were described [97,98]. Against four of the top
eight Listeria epitopes, robust CD4 T cell responses could be detected. BOTA utilizes information
on protein localization, transmembrane structure, and domain distribution, and outperformed
NetMHCIIpan for the prediction of the identified MHC II Listeria immunopeptides. BOTA also im-
proved predictive power when combined with NetMHCIIpan for publically available data on in-
flammatory bowel disease (IBD) over NetMHCIIpan alone.
Francisella tularensis
Recently, Gaur et al. mapped MHC class I peptides from F. tularensis presented on infected
human blood-derived immature dendritic cells (iDCs) [99]. The authors reported ten Francisella-
derived peptide sequences from ten different antigens and validated their findings in silico, calcu-
lating high HLA binding affinities and antigenicity scores for the three best scoring epitopes.
From identified antigens to effective vaccines
Ongoing improvements to immunopeptidomics technology will allow deeper digging into the
bacterial antigen repertoire in the future. Peptide splicing, a process generating nongenetically
determined immunopeptides (Box 2), was ignored in all of the previously-mentioned studies.
Since T cells can recognize bacterial spliced peptides [46,47], considering such peptides will
yield more complete antigen panels. Similarly, other PTMs, such as formylation or palmitoylation
(Box 3), can be found on bacterial immunopeptides, and even host cell-derived immunopeptides
might display altered modifications during infection [66]. Bacterial infection can also interfere with
host cell antigen presentation [80,100,101], and together with PTMs, such immunomodulatory
processes should be considered in future immunopeptidomics studies. Finally, even though
immunopeptidomics typically requires large amounts of starting material, recent innovations
have allowed downscaling to ca. 1E7 cells, and efforts are ongoing to downscale even further
[38,53,55,58]. Together with more sensitive mass spectrometers, these developments will ex-
pand the number of infection models that are accessible to immunopeptidomics.
With immunopeptidomics being applied to increasing numbers of bacterial infection models, the
question arises on how to select antigens from these studies to encode in effective next-generation
vaccines. Validation of identification and antigenicity of discovered epitopes is the crucial first step
prior to in vivo testing. While anticancer vaccines encode mutated epitopes that are tumor-specific8 Trends in Microbiology, Month 2021, Vol. xx, No. xx
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epitopes, ensuring HLA-independent protection of population majorities. There are currently no
guidelines on how to prioritize immunopeptidomics-derived antigens as bacterial vaccine candidates;
however, a few trends and principles start to surface from the previously-mentioned studieswhichwe
integrated in a proposed vaccine candidate prioritization strategy outlined in Figure 3.
First, proteins releasing most epitopes might represent immunodominant antigens. Ideally, these
antigens are picked up in different studies and presented on several HLA alleles on different cell
types, tissues or species, for example, the Mtb glfT2 and iniB antigens [75,77,80]. In case of little
overlap, antigens detected from cell types reflecting the replicative niche during in vivo infection
might be prioritized [94]. More sensitive future immunopeptidomics screens identifying hundreds
(instead of tens) of bacterial epitopes/screen are required to further substantiate a potential link
between epitope abundance and antigen immunodominance. Second, antigens eliciting good
immune responses often originate from the bacterial membrane or periphery, in line with close
contact of these surface proteins with the host intracellular milieu [77,80,88,96]. Third, combined
delivery of multiple immunopeptidomics-discovered antigens seems to provide better protection
than single antigens, allowing stable protection for different populations and omitting single anti-
gen shifts [80,85]. Of note, also general considerations and tools for vaccine antigen selection
should be taken into account, including prioritization of antigens conserved in clinical strains, ex-
clusion of harmful antigens (e.g., bacterial toxins) and avoidance of host- and microbiome-
























































































Figure 3. Proposed vaccine candidate prioritization strategy from immunopeptidomics studies. Bar char
representing the outcome of a hypothetical immunopeptidomics experiment on bacterially infected cells. The screen is
carried out in two different host cell types relevant for infection represented in gray (light gray, epithelial cells; dark gray
antigen-presenting cells, APCs). The y-axis depicts the number of identified peptide epitopes for each bacterial protein
antigen over the two screens. Antigens depicted in green are considered good vaccine candidates since they release the
highest number of epitopes over both screens. Often these candidate antigens are derived from the bacterial periphery
and are in close contact with the host intracellular milieu. Antigens in red are not considered suitable vaccine candidates
due to substantial toxicity (antigen A), sequence homology to microbiome (antigen B) or host proteins (antigen C), or low T
cell reactivity (antigen D). Encoding the four top candidates within a single mRNA vaccine formulation could facilitate broad
immune responses, while avoiding immune escape of the pathogen by single antigen shifts.
Trendt
,




Do immunopeptidomics screens on
bacterial infection models hold
information on which bacterial antigens
to select as vaccine candidates? Can
we use the abundance of identified
epitopes and recurrence in different
screens to prioritize their parent
antigens?
Which host cell type, tissue, or organ is
best suited to screen for antigens?
Should we screen infected APCs or
rather nonimmune (epithelial) cells for
pathogens that use the latter as a
replicative niche during in vivo
infection?
Will nucleic acid vaccines against intra-
cellular bacterial pathogens be equally
effective against cytosolic (MHC I pre-
sented) or vacuolar (MHC II presented)
pathogens?Antigens identified byMHC class I immunopeptidomics can be encoded quite easily into vaccines
against cytosolic pathogens that typically require strong cytotoxic CD8 T cell responses for infec-
tion clearance, such as L. monocytogenes [103]. Indeed, the encoded antigenic information will
be translated into bacterial proteins in the host cell cytosol ready for MHC I presentation. For
noncytosolic, vacuolar pathogens, such as Chlamydia or Salmonella, for which humoral and
CD4 T cell responses are typically more important [104,105], MHC II-identified antigens can be
encoded using secretion signal tags allowing uptake of the secreted bacterial antigens by profes-
sional APCs for MHC II presentation [106]. Here, care must be taken to avoid secretion-
associated glycosylation potentially inferring immune tolerance [107]. Of note, for many patho-
gens, protective immunity relies on both cellular and humoral immunity [108,109]. While classic
whole-pathogen or subunit vaccines typically elicit strong antibody responses, nucleic acid-
based vaccines now allow the induction of much stronger cytotoxic responses. For pathogens
such as Mtb, for which the contribution of cytotoxic responses has become clear in recent
years [108], MHC class I immunopeptidomics might help to design more effective nucleic acid-
based vaccines.
Concluding remarks and future perspectives
Immunopeptidomics hasmatured into a powerful technology for antigen discovery. Currently, the
technology has been applied to only a handful of intracellular bacterial pathogens, especially
Mycobacteria and Chlamydia, but with rising AMR, more studies are expected in the years to
come to shed light on burning questions in the field (see Outstanding questions). Discovered
antigens can be directly encoded in nucleic acid-based vaccines, constituting a versatile and
powerful vaccine development pipeline. Further improvements to increase the sensitivity of
immunopeptidomics studies are expected to boost the number of identified antigens and to
strengthen the golden alliance with viral vector and mRNA vaccine platforms, facilitating develop-
ment of effective, novel antibacterial vaccines.
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